[HTML][HTML] Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative …
GYH Lip, A Keshishian, A Kang, X Luo, N Atreja… - Journal of Thrombosis …, 2022 - Springer
Introduction There are a paucity of real-world data examining effectiveness and safety of non-
vitamin K antagonist oral anticoagulants (NOACs) and warfarin in nonvalvular atrial …
vitamin K antagonist oral anticoagulants (NOACs) and warfarin in nonvalvular atrial …
Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation
G Adeboyeje, G Sylwestrzak, JJ Barron, J White… - Journal of managed …, 2017 - jmcp.org
BACKGROUND: The use of non-vitamin K oral anticoagulants (NOACs) has increased
steadily following marketing approval; however, their relative safety in nonvalvular atrial …
steadily following marketing approval; however, their relative safety in nonvalvular atrial …
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin
GYH Lip, A Keshishian, S Kamble… - Thrombosis and …, 2016 - thieme-connect.com
In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs)
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …
Major bleeding complications and persistence with oral anticoagulation in non‐valvular atrial fibrillation: contemporary findings in real‐life Danish patients
M Lamberts, L Staerk, JB Olesen… - Journal of the …, 2017 - Am Heart Assoc
Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …
Differences in safety and efficacy of oral anticoagulants in patients with non‐valvular atrial fibrillation: A Bayesian analysis
Z Sun, Y Liu, Y Zhang, X Guo… - International Journal of …, 2019 - Wiley Online Library
Background Novel oral anticoagulants are the cornerstone of therapy for non‐valvular atrial
fibrillation patients to lower the risk of ischaemic stroke. Given the lack of head‐to‐head …
fibrillation patients to lower the risk of ischaemic stroke. Given the lack of head‐to‐head …
Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the …
GYH Lip, X Pan, S Kamble, H Kawabata… - … journal of clinical …, 2016 - Wiley Online Library
Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
[HTML][HTML] Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of …
Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …
[HTML][HTML] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
PG Tepper, J Mardekian, C Masseria, H Phatak… - PloS one, 2018 - journals.plos.org
Limited real-world data are available regarding the comparative safety of non-vitamin K
antagonist oral anticoagulants (NOACs). The objective of this retrospective claims …
antagonist oral anticoagulants (NOACs). The objective of this retrospective claims …
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants
S Halvorsen, W Ghanima, I Fride Tvete… - European Heart …, 2017 - academic.oup.com
Aims We aimed to evaluate bleeding risk in clinical practice in patients with atrial fibrillation
(AF) being prescribed dabigatran, rivaroxaban, or apixaban compared with warfarin …
(AF) being prescribed dabigatran, rivaroxaban, or apixaban compared with warfarin …
Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study
Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …
相关搜索
- fibrillation patients effectiveness and safety
- fibrillation patients oral anticoagulants
- oral anticoagulants effectiveness and safety
- fibrillation patients bleeding risk
- oral anticoagulants retrospective analysis
- fibrillation patients retrospective analysis
- differences in safety atrial fibrillation
- rates in patients atrial fibrillation
- retrospective analysis effectiveness and safety
- bleeding complications atrial fibrillation
- bayesian analysis atrial fibrillation
- meta analysis bleeding risk
- bleeding complications danish patients
- fibrillation patients defense population
- bleeding complications oral anticoagulation
- defense population effectiveness and safety